per-chart, page-853

Catalysts can happen very quickly, or it can be a slow realisation!!

Roche is a major player globally in the Pharma space and has spent billions in the DMD space… with very little revenue to show for it to date.

In the past 2 weeks, we have seen Roche pay Sarepta US$48m to forego an option in a DMD program (one must assume it is on the Dystrophin restoration side if it was with Sarepta). Concurrently they have announced a major trial in the DMD anti inflammatory space targeting bone and muscle strength!!!! Sound familiar!

There has been a massive rethink within Roche about how to treat DMD and where they want to spend the next few billion.

This is a seminal event for the treatment of DMD and where the future focus of drug development lies.

This isn’t little Percheron or Capricor.. it is a major global pharma that is deeply involved and connected in the DMD ecosystem.

Roche’s open label trial will run for 2 years and is structured very similar to ours (50 patients across 16 sites).

Global investors and corporations will now be able to put large funds into a the DMD inflammatory space now the leader has said this is the way forward.

How quickly PER gets recognized as part of the new future for DMD treatment is the unknown but with the PH2b fully enrolled, it’s probably sooner rather than later!

https://www.parentprojectmd.org/roche-announces-phase-ii-open-label-shield-dmd-study-to-assess-effect-of-satralizumab-on-bone-health-in-duchenne/